Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Saved in:
| Title: | Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. |
|---|---|
| Authors: | Brose MS; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Now at Sidney Kimmel Cancer Center, Jefferson Health, Philadelphia, PA, USA., Robinson BG; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Sherman SI; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jarzab B; Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska Curie National Research Institute of Oncology, Gliwice, Poland., Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Vaisman F; Endocrinology Service, Instituto Nacional de Câncer, Rio de Janeiro, Brazil., Hoff AO; Department of Endocrinology, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil., Hitre E; Department of Medical Oncology and Clinical Pharmacology 'B', Országos Onkológiai Intézet, Budapest, Hungary., Bowles DW; Division of Medical Oncology, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado, USA., Sen S; Exelixis, Inc., Alameda, California, USA., Oliver JW; Exelixis, Inc., Alameda, California, USA., Banerjee K; Exelixis, Inc., Alameda, California, USA., Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea., Capdevila J; Medical Oncology Department Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain. |
| Source: | Cancer [Cancer] 2022 Dec 15; Vol. 128 (24), pp. 4203-4212. Date of Electronic Publication: 2022 Oct 19. |
| Publication Type: | Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.34493 |
